Cold, Flu & Cough

What is the Common Cold?

The common cold, also known as rhinopharyngitis, is a type of respiratory tract infection caused by a virus.

Walking Pneumonia Versus Common Cold

Does the 'Stomach Flu' Vaccine Prevent Type I Diabetes?

Walking Pneumonia Versus Common Cold

Influenza Infection in Animals

Risk Factors and Walking Pneumonia Prevention

Latest Cold, Flu & Cough News and Research

Early monoclonal antibody therapies beneficial for COVID-19, finds study

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.

13 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

Syphilis cases in California drive a record-setting year for STDs nationwide

In certain circles of San Francisco, a case of syphilis can be as common and casual as the flu, to the point where Billy Lemon can't even remember how many times he's had it.

13 Apr 2021

Biology of single-celled organisms reveals potential treatment target for COPD

In a series of experiments that began with amoebas -- single-celled organisms that extend podlike appendages to move around -- Johns Hopkins Medicine scientists say they have identified a genetic pathway that could be activated to help sweep out mucus from the lungs of people with chronic obstructive pulmonary disease a widespread lung ailment.

13 Apr 2021

ACE2 homology in laboratory and wild animals

A new preprint research paper posted to the bioRxiv server describes the conservation of an important receptor gene for the virus among several animal species that live in close contact or proximity to humans.

13 Apr 2021

SARS-CoV-2 viable 21 days in blood, mucus, semen, urine, but just 24 hours in breast milk

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), spreads through respiratory droplets and aerosols expelled when infected individuals cough, sneeze, breathe or sing.

13 Apr 2021

Monitoring CO2 to assess risk of indoor airborne SARS-CoV-2 transmission

In the study, which appeared on the pre-print server medRxiv, the team developed a general mathematical theory to predict airborne transmission risk from carbon dioxide (CO2) time series in real-time and clarify different estimates that steer the guideline. The study findings were based on the assessment of transmission risk and implementing the guideline by CO2 monitoring in university classrooms and office spaces.

13 Apr 2021

Could Zebrafish larvae be a novel animal model for SARS-CoV-2?

Researchers based in Paris, France, have explored the potential use of zebrafish larvae as animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These larvae are small and cheap, so could prove a suitable medium for rapid mass testing of the disease.

13 Apr 2021

Children less likely to spread SARS-CoV-2 than adults

A study conducted by researchers in Canada suggests that children may be less likely than adults to spread the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

12 Apr 2021

Researchers uncover a new source of energy expending brown fat cells

A new source of energy expending brown fat cells has been uncovered by researchers at the Joslin Diabetes Center, which they say points towards potential new therapeutic options for obesity.

12 Apr 2021

Research may lead to a significant breakthrough in the battle against deadly brain tumors

Groundbreaking research from Tel Aviv University may lead to a significant breakthrough in the battle against deadly brain cancer.

12 Apr 2021

UHN performed first double-lung transplant after COVID-19 in Canada

University Health Network has performed what is believed to be the first lung transplant in Canada on a patient whose lungs were irreparably damaged by COVID-19.

12 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

COVID19's cytokine storm ushers in a local complement storm in the lungs

A new study published in the journal Science Immunology analyzed lung epithelial cells from patients infected with COVID-19 and found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the complement system as a dangerous weapon for viral infection.

12 Apr 2021

More than 100 economies receive life-saving COVID-19 vaccines from COVAX

More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on 24 February 2021.

12 Apr 2021

Broadly neutralizing antibodies show promise in preventing tick-borne encephalitis in mice

Tick-borne encephalitis is a disease just as nasty as it sounds. Once bitten by an infected tick, some people develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease--brain swelling, memory loss, and cognitive decline.

9 Apr 2021